PMDA drug package insert
ナルフラフィン塩酸塩カプセル2.5μg「BMD」
PMDA Prescription drug · 株式会社ビオメディクス · package insert May 12, 2023
Key facts
| Brand names | ナルフラフィン塩酸塩カプセル2.5μg「BMD」 |
|---|---|
| Nonproprietary names | ナルフラフィン塩酸塩 |
| Companies | 製造販売元／株式会社ビオメディクス |
| Product type | Prescription drug |
| Therapeutic category | 経口そう痒症改善剤 |
| Therapeutic category codes | 87119 |
| YJ codes | 1190015M1045 |
| Approval numbers | 23000AMX00316000 |
| Package insert edition | 第3版 |
| Package insert date | May 12, 2023 |
| PMDA document key | 650208_1190015M1045_1 |
| PMDA company code | 650208 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: